MCID: OPT003
MIFTS: 55

Opiate Dependence

Categories: Mental diseases

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Name: Opiate Dependence 12 15
Opioid Dependence 77 56 17
Opioid-Related Disorders 74
Opioid Type Dependence 12
Opiate Addiction 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2559
ICD9CM 36 304.0 304.00
MeSH 45 D009293
SNOMED-CT 69 75544000
ICD10 34 F11.2

Summaries for Opiate Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid dependence, is related to opioid dependence 1 and morphine dependence. An important gene associated with Opiate Dependence is ODS1 (Opioid Dependence, Susceptibility To, 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Buprenorphine and Naloxone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and pituitary, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Opioid use disorder is a problematic pattern of opioid use that causes significant impairment or... more...

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 opioid dependence 1 34.0 ODS1 OPRM1
2 morphine dependence 31.5 CREB1 OPRD1 OPRK1 OPRM1
3 opioid addiction 31.2 DRD2 OPRD1 OPRK1 OPRM1
4 heroin dependence 30.8 DRD2 OPRD1 OPRM1 PDYN
5 psychotic disorder 30.3 DRD2 DRD3 SLC6A4 TPH1
6 withdrawal disorder 30.0 OPRM1 PDYN POMC
7 neonatal abstinence syndrome 29.9 OPRD1 OPRK1 OPRM1
8 anxiety 29.9 OPRL1 SLC6A4 TPH1
9 substance abuse 29.9 DRD2 DRD3 SLC6A4
10 personality disorder 29.8 DRD2 SLC6A4 TPH1
11 conduct disorder 29.8 DRD2 SLC6A4 TPH1
12 alcohol abuse 29.6 DRD2 DRD3 SLC6A4
13 schizoaffective disorder 29.5 DRD2 DRD3 SLC6A4
14 schizophrenia 29.3 DRD2 DRD3 SLC6A4 TH TPH1
15 attention deficit-hyperactivity disorder 29.2 DRD2 DRD3 OPRM1 SLC6A4 TH TPH1
16 pain agnosia 29.2 OPRK1 OPRL1 OPRM1 PDYN POMC
17 bipolar disorder 28.9 CREB1 DRD2 DRD3 SLC6A4 TH TPH1
18 mood disorder 28.9 CREB1 DRD2 DRD3 POMC SLC6A4 TH
19 disease of mental health 28.4 DRD2 DRD3 OPRM1 PDYN POMC SLC6A4
20 alcohol dependence 27.5 DRD2 DRD3 OPRD1 OPRK1 OPRL1 OPRM1
21 drug dependence 27.4 DRD2 DRD3 OPRD1 OPRK1 OPRL1 OPRM1
22 avoidant personality disorder 10.4 SLC6A4 TPH1
23 gangliocytoma 10.4 POMC TH
24 acidophil adenoma 10.3 IGF1 POMC
25 pituitary infarct 10.3 IGF1 POMC
26 sick building syndrome 10.3 POMC VEGFA
27 empty sella syndrome 10.3 IGF1 POMC
28 mental depression 10.2 POMC SLC6A4 TPH1
29 sheehan syndrome 10.2 IGF1 POMC
30 toxic encephalopathy 10.2 CREB1 NGF TH
31 cerebral hypoxia 10.2 CREB1 IGF1
32 chronic fatigue syndrome 10.2 IGF1 POMC SLC6A4
33 endocrine organ benign neoplasm 10.2 IGF1 NGF POMC
34 anorexia nervosa 10.2 IGF1 POMC SLC6A4
35 pituitary tumors 10.2 IGF1 POMC VEGFA
36 hyperpituitarism 10.2 IGF1 POMC
37 west syndrome 10.2 POMC TH TPH1
38 nervous system disease 10.1 NGF TH VEGFA
39 somatoform disorder 10.1 NGF OPRM1 TPH1
40 gonadal disease 10.1 IGF1 POMC VEGFA
41 sexual disorder 10.1
42 central nervous system disease 10.1 NGF SLC6A4 TH
43 phobic disorder 10.1 OPRK1 SLC6A4
44 retrograde amnesia 10.1 PDYN POMC SLC6A4
45 ovarian disease 10.1 IGF1 NGF VEGFA
46 hepatitis 10.1
47 depression 10.1
48 alcohol-induced mental disorder 10.0 DRD2 SLC6A4
49 polysubstance abuse 10.0 DRD2 DRD3
50 pol iii-related leukodystrophies 10.0

Graphical network of the top 20 diseases related to Opiate Dependence:



Diseases related to Opiate Dependence

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.32 CREB1 DRD2 DRD3 NGF OPRD1 OPRK1
2 homeostasis/metabolism MP:0005376 10.24 CREB1 DRD2 DRD3 IGF1 NGF OPRD1
3 growth/size/body region MP:0005378 10.18 CREB1 DRD2 DRD3 IGF1 NGF OPRM1
4 cardiovascular system MP:0005385 10.16 CREB1 DRD2 DRD3 IGF1 NGF POMC
5 integument MP:0010771 10.13 DRD2 IGF1 NGF OPRD1 OPRK1 OPRL1
6 endocrine/exocrine gland MP:0005379 10.09 CREB1 DRD2 IGF1 OPRK1 OPRM1 POMC
7 adipose tissue MP:0005375 10.04 DRD2 DRD3 IGF1 OPRM1 PDYN POMC
8 nervous system MP:0003631 10 CREB1 DRD2 DRD3 IGF1 NGF OPRD1
9 muscle MP:0005369 9.8 CREB1 DRD2 IGF1 NGF SLC6A4 TPH1
10 no phenotypic analysis MP:0003012 9.56 DRD2 NGF OPRD1 OPRM1 PDYN POMC
11 normal MP:0002873 9.28 CREB1 DRD2 IGF1 NGF OPRL1 OPRM1

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 311)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52485-79-7 644073 40400
2
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
3
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 16590-41-3 5360515
4
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
5
Methadone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
8
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 38396-39-3, 2180-92-9 2474
9
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
10
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
11
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
12
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
13
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable 54-11-5 89594 942
14
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
15
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
16
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60142-96-3 3446
17
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-42-6 5284603
18
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
19
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
20
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
21
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
22
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
23
Acetaminophen Approved Phase 4,Not Applicable 103-90-2 1983
24
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
25
Codeine Approved, Illicit Phase 4 76-57-3 5284371
26
Cobicistat Approved Phase 4 1004316-88-4
27
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
28
Tenofovir Approved, Experimental, Investigational Phase 4 147127-20-6 464205
29
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
30 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Analgesics, Opioid Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
36 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37
Heroin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5462328
38 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antiviral Agents Phase 4,Phase 3,Phase 1,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 503)
# Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice Completed NCT00007527 Phase 4 naloxone;buprenorphine
4 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
5 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
6 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
7 Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
8 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
9 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
10 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
11 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
12 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
13 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
14 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
15 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
16 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
17 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
18 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
19 HIV, Buprenorphine, and the Criminal Justice System (STRIDE2) Completed NCT03583138 Phase 4 buprenorphine
20 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
21 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
22 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
23 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
24 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
25 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
26 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
27 Desvenlafaxine in Opioid-Dependent Patients Completed NCT02200406 Phase 4 Desvenlafaxine
28 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
29 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
30 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
31 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
32 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4 Naltrexone
33 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
34 Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
35 A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic Recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
36 Houston Emergency Opioid Engagement System Recruiting NCT03396276 Phase 4 Suboxone
37 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
38 Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
39 A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse Recruiting NCT03033732 Phase 4 Methadone;Buprenorphine-Naloxone
40 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
41 Switch to Genvoya Followed by HCV Therapy With Epclusa in Patients With HIV/HCV Co-Infection on Methadone Recruiting NCT03549312 Phase 4 Genvoya;Epclusa
42 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
43 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Active, not recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
44 Extended Release Naltrexone for Opioid-Dependent Youth Active, not recruiting NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
45 Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings Enrolling by invitation NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
46 Liposomal Bupivacaine in Ambulatory Hand Surgery Enrolling by invitation NCT02933814 Phase 4 Liposomal Bupivicaine
47 XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept Not yet recruiting NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
48 Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption Not yet recruiting NCT03534102 Phase 4 Improved Opioid-Tapering Instructions
49 Gabapentin Regimens and Their Effects on Opioid Consumption Not yet recruiting NCT03334903 Phase 4 Gabapentin
50 Anxiety in Recovering Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

42
Brain, Testes, Pituitary, Liver, Bone, Eye, Skin

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 1022)
# Title Authors Year
1
Editorial Commentary: Scoping Knees With Osteoarthritis and Opioid Dependence? Brace Yourself for Postop Pain. ( 30712633 )
2019
2
Opioid Dependence and Health Care Utilization After Decompression and Fusion in Patients With Adult Degenerative Scoliosis. ( 30015717 )
2019
3
Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence. ( 30920187 )
2019
4
Mindfulness-based therapy modulates default-mode network connectivity in patients with opioid dependence. ( 30926325 )
2019
5
Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use. ( 30936032 )
2019
6
From pain treatment to opioid dependence: a qualitative study of the environmental influence on codeine use in UK adults. ( 30948580 )
2019
7
Opioid Dependence in Pregnancy. ( 30956479 )
2019
8
Assessment of Subjective Sleep Problems in Men With Opioid Dependence Maintained on Buprenorphine. ( 30964756 )
2019
9
VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence. ( 30983500 )
2019
10
In utero exposure to norbuprenorphine, a major metabolite of buprenorphine, induces fetal opioid dependence and leads to neonatal opioid withdrawal syndrome. ( 31028107 )
2019
11
Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. ( 31046774 )
2019
12
Can Tramadol be Used for Maintenance Treatment of Opioid Dependence? ( 30395757 )
2019
13
Interrelationship of Opioid Dependence, Impaired Impulse Control, and Depressive Symptoms: An Open-Label Cross-Sectional Study of Patients in Maintenance Therapy. ( 30453290 )
2019
14
Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial. ( 30460781 )
2019
15
Transcranial direct current stimulation to prevent and treat surgery-induced opioid dependence: a systematic review. ( 30516441 )
2019
16
Treating Opioid Dependence: Pain Medicine Physiology of Tolerance and Addiction. ( 30614846 )
2019
17
Rostral and Caudal Ventral Tegmental Area GABAergic Inputs to Different Dorsal Raphe Neurons Participate in Opioid Dependence. ( 30638902 )
2019
18
Gender differences in subjective stress and neuroendocrine response to a stress task among individuals with opioid dependence: A pilot study. ( 30640146 )
2019
19
Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. ( 30701615 )
2019
20
Perinatal Navigator Approach to Smoking Cessation for Women With Prevalent Opioid Dependence. ( 30724661 )
2019
21
Predicting opioid dependence from electronic health records with machine learning. ( 30728857 )
2019
22
Transdermal buprenorphine patch: Potential for role in management of opioid dependence. ( 30772733 )
2019
23
Risk, reversibility and resilience of brain circuitries linked to opioid dependence: A diffusion tensor imaging study of actively opioid-using subjects and three comparison groups. ( 30785033 )
2019
24
Genomewide Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women. ( 30874594 )
2019
25
Meeting the challenges of opioid dependence in China: experience of opioid agonist treatment. ( 30893091 )
2019
26
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study. ( 30566177 )
2018
27
Regional cerebral blood flow in opiate dependence relates to substance use and neuropsychological performance. ( 28627790 )
2018
28
Opiate Dependence or Addiction?: A Review of the Centers for Disease Control and Prevention Guidelines for Management of Chronic Pain. ( 29505462 )
2018
29
Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP. ( 29843726 )
2018
30
The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial. ( 30157924 )
2018
31
Factors predicting opioid dependence in patients undergoing surgery for degenerative spondylolisthesis: analysis from the MarketScan databases. ( 29914294 )
2018
32
Health care utilization and overall costs based on opioid dependence in patients undergoing surgery for degenerative spondylolisthesis. ( 29712535 )
2018
33
Alcohol use disorder and associated physical health complications and treatment amongst individuals with and without opioid dependence: A case-control study. ( 29807218 )
2018
34
Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS/MS. ( 30391868 )
2018
35
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. ( 28402682 )
2018
36
Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. ( 28576389 )
2018
37
Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence. ( 28593748 )
2018
38
An analysis of genetic association in opioid dependence susceptibility. ( 28656735 )
2018
39
Perceived stigma and social support in treatment for pharmaceutical opioid dependence. ( 28884866 )
2018
40
Compulsivity in opioid dependence. ( 28918267 )
2018
41
Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence. ( 28930612 )
2018
42
Creating opioid dependence in the emergency department. ( 28958216 )
2018
43
Large variation in measures used to assess outcomes of opioid dependence treatment: A systematic review of longitudinal observational studies. ( 28971544 )
2018
44
Pilot Study of a Tailored Smoking Cessation Intervention for Individuals in Treatment for Opioid Dependence. ( 29059389 )
2018
45
Opioid dependence and pregnancy in early twentieth-century America. ( 29130600 )
2018
46
Neonatal Outcomes in a Medicaid Population With Opioid Dependence. ( 29155919 )
2018
47
Healthcare utilization and costs associated with treatment for opioid dependence. ( 29320915 )
2018
48
What are the characteristics of vitamin D metabolism in opioid dependence? An exploratory longitudinal study in Australian primary care. ( 29331964 )
2018
49
Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. ( 29333880 )
2018
50
Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients. ( 29346444 )
2018

Variations for Opiate Dependence

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CREB1 DRD2 DRD3 IGF1 NGF OPRD1
2
Show member pathways
13.36 DRD2 DRD3 OPRD1 OPRK1 OPRL1 OPRM1
3
Show member pathways
12.8 CREB1 DRD2 DRD3 OPRM1 TH VEGFA
4
Show member pathways
12.31 CREB1 OPRM1 PDYN POMC
5 12.17 CREB1 NGF OPRM1 POMC TH TPH1
6
Show member pathways
11.74 CREB1 DRD2 PDYN TH
7
Show member pathways
11.68 DRD2 DRD3 TH
8 11.68 OPRD1 OPRM1 POMC VEGFA
9 11.65 CREB1 NGF SLC6A4 TH TPH1 VEGFA
11 11.46 IGF1 NGF TH VEGFA
12 11.26 DRD2 IGF1 NGF
13
Show member pathways
10.89 TH TPH1
14 10.88 DRD2 DRD3
15 10.83 CREB1 TH

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.98 DRD2 DRD3 OPRD1 OPRK1 OPRL1 OPRM1
2 axon GO:0030424 9.8 CREB1 DRD2 NGF OPRM1 TH
3 dendrite GO:0030425 9.73 DRD2 NGF OPRK1 OPRM1 PDYN TH
4 perikaryon GO:0043204 9.62 DRD2 OPRK1 OPRM1 TH
5 dopaminergic synapse GO:0098691 9.46 DRD2 DRD3
6 axon terminus GO:0043679 9.46 DRD2 OPRD1 OPRK1 PDYN
7 spine apparatus GO:0097444 9.37 OPRD1 OPRM1
8 integral component of postsynaptic membrane GO:0099055 9.26 DRD2 OPRK1 OPRM1 SLC6A4
9 integral component of presynaptic membrane GO:0099056 9.02 DRD2 OPRD1 OPRK1 OPRM1 SLC6A4

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.99 OPRD1 OPRM1 POMC VEGFA
2 response to drug GO:0042493 9.99 CREB1 DRD2 DRD3 SLC6A4 TH
3 negative regulation of gene expression GO:0010629 9.98 CREB1 IGF1 OPRD1 VEGFA
4 response to estradiol GO:0032355 9.88 OPRL1 SLC6A4 TH
5 response to hypoxia GO:0001666 9.88 CREB1 DRD2 SLC6A4 TH VEGFA
6 circadian rhythm GO:0007623 9.86 CREB1 SLC6A4 TPH1
7 cellular response to growth factor stimulus GO:0071363 9.84 CREB1 OPRD1 TH
8 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.83 OPRD1 OPRK1 OPRM1
9 memory GO:0007613 9.83 CREB1 NGF SLC6A4 TH
10 sensory perception of pain GO:0019233 9.82 OPRK1 OPRL1 OPRM1
11 social behavior GO:0035176 9.82 DRD3 SLC6A4 TH
12 visual learning GO:0008542 9.81 CREB1 DRD2 DRD3
13 response to nicotine GO:0035094 9.8 CREB1 DRD2 TH
14 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.8 OPRD1 OPRK1 OPRL1 OPRM1
15 response to ethanol GO:0045471 9.8 DRD2 DRD3 OPRK1 OPRM1 TH
16 response to amphetamine GO:0001975 9.77 DRD2 DRD3 TH
17 negative regulation of blood pressure GO:0045776 9.76 DRD2 DRD3 OPRL1
18 positive regulation of receptor internalization GO:0002092 9.73 DRD2 VEGFA
19 positive regulation of neuroblast proliferation GO:0002052 9.73 DRD2 VEGFA
20 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.73 DRD2 DRD3
21 positive regulation of Ras protein signal transduction GO:0046579 9.73 IGF1 NGF
22 behavioral response to cocaine GO:0048148 9.73 DRD2 DRD3 OPRK1
23 response to cocaine GO:0042220 9.73 DRD2 DRD3 OPRK1 OPRM1
24 dopamine receptor signaling pathway GO:0007212 9.72 DRD2 DRD3
25 eye photoreceptor cell development GO:0042462 9.72 TH VEGFA
26 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD3
27 positive regulation of long-term synaptic potentiation GO:1900273 9.72 CREB1 DRD2
28 mammary gland alveolus development GO:0060749 9.72 TPH1 VEGFA
29 synaptic transmission, dopaminergic GO:0001963 9.72 DRD2 DRD3 TH
30 positive regulation of CREB transcription factor activity GO:0032793 9.71 OPRD1 VEGFA
31 response to growth factor GO:0070848 9.71 OPRM1 TH
32 dopamine metabolic process GO:0042417 9.71 DRD2 DRD3
33 prepulse inhibition GO:0060134 9.71 DRD2 DRD3
34 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A4 TH
35 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 DRD3
36 positive regulation of urine volume GO:0035810 9.7 DRD2 OPRL1
37 G protein-coupled receptor internalization GO:0002031 9.69 DRD2 DRD3
38 estrous cycle GO:0044849 9.69 OPRK1 OPRL1 OPRM1
39 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.68 DRD3 OPRM1
40 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD2 DRD3
41 aromatic amino acid family metabolic process GO:0009072 9.68 TH TPH1
42 behavior GO:0007610 9.67 OPRK1 OPRL1
43 behavioral response to ethanol GO:0048149 9.67 DRD2 OPRM1
44 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 DRD2 OPRL1
45 regulation of sensory perception of pain GO:0051930 9.67 OPRD1 OPRK1 OPRL1 OPRM1
46 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.66 OPRL1 OPRM1
47 locomotory behavior GO:0007626 9.65 DRD2 DRD3 OPRK1 OPRM1 TH
48 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.64 DRD2 DRD3
49 negative regulation of dopamine receptor signaling pathway GO:0060160 9.63 DRD2 DRD3
50 sensory perception GO:0007600 9.63 OPRK1 OPRL1 OPRM1

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.85 DRD2 DRD3 OPRD1 OPRK1 OPRL1 OPRM1
2 adrenergic receptor activity GO:0004935 9.46 DRD2 DRD3
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3
4 receptor serine/threonine kinase binding GO:0033612 9.4 OPRD1 OPRK1
5 dopamine binding GO:0035240 9.33 DRD2 DRD3 TH
6 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD2 DRD3
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.26 TH TPH1
8 neuropeptide binding GO:0042923 9.26 OPRD1 OPRK1 OPRL1 OPRM1
9 opioid receptor activity GO:0004985 8.92 OPRD1 OPRK1 OPRL1 OPRM1

Sources for Opiate Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....